Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood-Based Proteomic Test to Enable Early Lung Cancer Detection

By LabMedica International staff writers
Posted on 05 Feb 2025

Lung cancer is the leading cause of cancer-related deaths globally. More...

More than 70% of cases are diagnosed at an advanced stage, but patients detected in the first stage have a 12-fold better five-year survival rate compared to those diagnosed at stage four, emphasizing the critical importance of early detection in improving outcomes. Now, a simple blood test to detect one of the deadliest cancers early aims to address this critical problem.

Oxford Cancer Analytics (OXcan; Oxford, UK) is focused on developing and globally commercializing innovative, minimally invasive liquid biopsy blood tests for early cancer detection. OXcan emerged from breakthroughs in combining advanced proteomics with tailored machine learning, transforming early cancer detection through blood tests. The company has created a patented approach, an advanced proteomics lab, and a platform dedicated to advancing the field of liquid biopsy. With a team of oncology innovation and machine learning experts, OXcan applies cutting-edge research techniques to analyze liquid biopsy data. In earlier studies, the company's machine learning models significantly improved detection rates for eight different cancer types by refining thousands of proteins into key biomarker signatures.

OXcan’s protein-based blood test identifies a molecular signature in patients at high risk for lung cancer. This simple, affordable, and precise blood test has the potential to facilitate earlier diagnoses and increase the number of individuals tested for lung cancer. The company has formed global partnerships to deploy the test on scalable platforms worldwide. OXcan is currently collaborating with over 20 healthcare centers across three continents, including pioneers in lung cancer screening, to refine and implement the technology. The company's diverse global biobank helps ensure more reliable biomarker identification across various populations, enhancing the test’s global applicability. Moreover, OXcan leverages advanced proteomics technology to detect a broader range of proteins, offering a more thorough understanding of the disease. The power of the OXcan proteomics biomarker discovery platform, coupled with the data generated, positions the company ahead of other liquid biopsy competitors, demonstrating superior performance in detecting early-stage lung cancer.

“Having developed blood-based proteomic tests for lung cancer for over two decades, I appreciate the difficulty of detecting cancers early through liquid biopsy,” said Dr. Heinrich Roder, SVP R&D at OXcan. “Convinced that OXcan’s unique approach can address this clinical need, I feel privileged to join the team. Together, our plan is to offer this novel technological approach to large markets worldwide to start a new era of early detection and improve patient outcomes.”

Related Links:
OXcan


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
Silver Member
Rapid Test Reader
DIA5000
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.